288 related articles for article (PubMed ID: 22091432)
1. Innovative Therapies against Human Glioblastoma Multiforme.
Cimini A; Ippoliti R
ISRN Oncol; 2011; 2011():787490. PubMed ID: 22091432
[TBL] [Abstract][Full Text] [Related]
2. Quantitative analysis of EGFRvIII cellular signaling networks reveals a combinatorial therapeutic strategy for glioblastoma.
Huang PH; Mukasa A; Bonavia R; Flynn RA; Brewer ZE; Cavenee WK; Furnari FB; White FM
Proc Natl Acad Sci U S A; 2007 Jul; 104(31):12867-72. PubMed ID: 17646646
[TBL] [Abstract][Full Text] [Related]
3. Current Perspectives on Therapies, Including Drug Delivery Systems, for Managing Glioblastoma Multiforme.
Bhaskaran M; Devegowda VG; Gupta VK; Shivachar A; Bhosale RR; Arunachalam M; Vaishnavi T
ACS Chem Neurosci; 2020 Oct; 11(19):2962-2977. PubMed ID: 32945654
[TBL] [Abstract][Full Text] [Related]
4. Overcoming the blood-brain tumor barrier for effective glioblastoma treatment.
van Tellingen O; Yetkin-Arik B; de Gooijer MC; Wesseling P; Wurdinger T; de Vries HE
Drug Resist Updat; 2015 Mar; 19():1-12. PubMed ID: 25791797
[TBL] [Abstract][Full Text] [Related]
5. Targeting cancer stem cells in glioblastoma multiforme using mTOR inhibitors and the differentiating agent all-trans retinoic acid.
Friedman MD; Jeevan DS; Tobias M; Murali R; Jhanwar-Uniyal M
Oncol Rep; 2013 Oct; 30(4):1645-50. PubMed ID: 23877261
[TBL] [Abstract][Full Text] [Related]
6. EGFRvIII as a promising target for antibody-based brain tumor therapy.
Kuan CT; Wikstrand CJ; Bigner DD
Brain Tumor Pathol; 2000; 17(2):71-8. PubMed ID: 11210174
[TBL] [Abstract][Full Text] [Related]
7. Aptamer targeting EGFRvIII mutant hampers its constitutive autophosphorylation and affects migration, invasion and proliferation of glioblastoma cells.
Camorani S; Crescenzi E; Colecchia D; Carpentieri A; Amoresano A; Fedele M; Chiariello M; Cerchia L
Oncotarget; 2015 Nov; 6(35):37570-87. PubMed ID: 26461476
[TBL] [Abstract][Full Text] [Related]
8. EGFR and EGFRvIII Promote Angiogenesis and Cell Invasion in Glioblastoma: Combination Therapies for an Effective Treatment.
Keller S; Schmidt MHH
Int J Mol Sci; 2017 Jun; 18(6):. PubMed ID: 28629170
[TBL] [Abstract][Full Text] [Related]
9. Nanocarriers for the treatment of glioblastoma multiforme: Current state-of-the-art.
Karim R; Palazzo C; Evrard B; Piel G
J Control Release; 2016 Apr; 227():23-37. PubMed ID: 26892752
[TBL] [Abstract][Full Text] [Related]
10. Crosstalk between the urokinase-type plasminogen activator receptor and EGF receptor variant III supports survival and growth of glioblastoma cells.
Hu J; Jo M; Cavenee WK; Furnari F; VandenBerg SR; Gonias SL
Proc Natl Acad Sci U S A; 2011 Sep; 108(38):15984-9. PubMed ID: 21896743
[TBL] [Abstract][Full Text] [Related]
11. Expression of activated epidermal growth factor receptors, Ras-guanosine triphosphate, and mitogen-activated protein kinase in human glioblastoma multiforme specimens.
Feldkamp MM; Lala P; Lau N; Roncari L; Guha A
Neurosurgery; 1999 Dec; 45(6):1442-53. PubMed ID: 10598712
[TBL] [Abstract][Full Text] [Related]
12. Nasal Drug Delivery of Anticancer Drugs for the Treatment of Glioblastoma: Preclinical and Clinical Trials.
Bruinsmann FA; Richter Vaz G; de Cristo Soares Alves A; Aguirre T; Raffin Pohlmann A; Stanisçuaski Guterres S; Sonvico F
Molecules; 2019 Nov; 24(23):. PubMed ID: 31779126
[TBL] [Abstract][Full Text] [Related]
13. Current Therapeutic Advances Targeting EGFR and EGFRvIII in Glioblastoma.
Padfield E; Ellis HP; Kurian KM
Front Oncol; 2015; 5():5. PubMed ID: 25688333
[TBL] [Abstract][Full Text] [Related]
14. Targeting EGFRvIII for glioblastoma multiforme.
Yang J; Yan J; Liu B
Cancer Lett; 2017 Sep; 403():224-230. PubMed ID: 28649003
[TBL] [Abstract][Full Text] [Related]
15. Response to erlotinib in recurrent glioblastoma multiforme showing coexpression of EGFRvIII and PTEN.
Custodio A; Calles A; Pérez-Segura P
Clin Transl Oncol; 2010 Apr; 12(4):310-4. PubMed ID: 20462843
[TBL] [Abstract][Full Text] [Related]
16. Epidermal growth factor receptor inhibition for the treatment of glioblastoma multiforme and other malignant brain tumours.
Halatsch ME; Schmidt U; Behnke-Mursch J; Unterberg A; Wirtz CR
Cancer Treat Rev; 2006 Apr; 32(2):74-89. PubMed ID: 16488082
[TBL] [Abstract][Full Text] [Related]
17. Toward intracellular targeted delivery of cancer therapeutics: progress and clinical outlook for brain tumor therapy.
Pandya H; Debinski W
BioDrugs; 2012 Aug; 26(4):235-44. PubMed ID: 22671766
[TBL] [Abstract][Full Text] [Related]
18. Present trend in the primary treatment of aggressive malignant glioma: glioblastoma multiforme.
Parvez T
Technol Cancer Res Treat; 2008 Jun; 7(3):241-8. PubMed ID: 18473496
[TBL] [Abstract][Full Text] [Related]
19. The EGFRvIII variant in glioblastoma multiforme.
Gan HK; Kaye AH; Luwor RB
J Clin Neurosci; 2009 Jun; 16(6):748-54. PubMed ID: 19324552
[TBL] [Abstract][Full Text] [Related]
20. LRIG1 negatively regulates the oncogenic EGF receptor mutant EGFRvIII.
Stutz MA; Shattuck DL; Laederich MB; Carraway KL; Sweeney C
Oncogene; 2008 Sep; 27(43):5741-52. PubMed ID: 18542056
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
